Riskpilot← Back to searchSign inGet full accessPHARMA NORGE AS
ASActiveOrg 822561772Kyrkjevegen 45, 6230 SykkylvenDetaljhandel utenom utsalgssted ellers · NACE 47990Est. 20190 employees
Revenue 2023
NOK 3,6M
-23% vs 2022
EBITDA margin
9.0%
+154% vs 2022
Equity ratio
-185.5%
Financial strength
Net profit 2023
NOK 133K
+117% vs 2022
| Revenue | NOK 3,6M | -23% |
| EBITDA | NOK 323K | +154% |
| Net profit | NOK 133K | +117% |
| Total assets | NOK 1,7M | +9% |
| Equity | NOK -3,2M | +4% |
| Employees | 0 | — |
Legal name
PHARMA NORGE AS
Org number
822561772
Legal form
Aksjeselskap
NACE code
47990 · Detaljhandel utenom utsalgssted ellers
Founded
29. mars 2019
Share capital
NOK 500 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Daglig leder eller styrets leder hver for seg.
Company purpose
Salg av helsekostprodukter spesielt rettet mot dyr, og andre produkter/tjenester som naturlig hører sammen med dette.
Address
Kyrkjevegen 45, 6230 Sykkylven
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 20 | 1 404 | 4 900 | 4 613 | 3 568 |
| Staff expenses | −0 | −0 | −8 | −0 | −0 |
| EBITDA | −190 | −1 286 | −1 583 | −599 | 323 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −190 | −1 286 | −1 583 | −599 | 323 |
| Net financials | 1 | 0 | 7 | −184 | −189 |
| Profit before tax | −189 | −1 286 | −1 576 | −783 | 133 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −189 | −1 286 | −1 576 | −783 | 133 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 311 | 1 327 | 1 073 | 1 587 | 1 725 |
| Equity | 311 | −975 | −2 551 | −3 334 | −3 200 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 2 301 | 3 624 | 4 921 | 4 925 |
| Total debt | 0 | 2 301 | 3 624 | 4 921 | 4 925 |
EBITDA margin
9.0%
This company
15.8%
Market median
-43% vs market
20192023
Equity ratio
-185.5%
This company
38.2%
Market median
-586% vs market
20192023
Return on equity
13347800.0%
This company
18.4%
Market median
+72542291% vs market
20192023
Net profit margin
3.7%
This company
8.1%
Market median
-54% vs market
20192023
Asset turnover
2.07×
This company
1.12×
Market median
+85% vs market
20192023
Debt / equity
1.54×
This company
0.62×
Market median
-148% vs market
20192023
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-03-06 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RM Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Nutripharma International As | Company | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pharma Norge As
PHARMA NORGE AS Board members of PHARMA NORGE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rune Meyer | Chief Executive Officer | 0 companies |
| Thomas Kristoffer Storvestre | Chairman | 0 companies |
| Aasmund Olav Brevik | Board of Directors | 0 companies |
| Anders Lindstad | Chairman | 0 companies |